Cost Of Revenue - Epizyme Inc (F:EPE) - Alpha Spread
E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

Epizyme Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Epizyme Inc
Cost of Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
E
Epizyme Inc
F:EPE
Cost of Revenue
-$13m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.3B
CAGR 3-Years
0%
CAGR 5-Years
-20%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$11.4B
CAGR 3-Years
-22%
CAGR 5-Years
-22%
CAGR 10-Years
-12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.4B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-33%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
-3%
CAGR 5-Years
-26%
CAGR 10-Years
-26%

See Also

What is Epizyme Inc's Cost of Revenue?
Cost of Revenue
-13m USD

Based on the financial report for Jun 30, 2022, Epizyme Inc's Cost of Revenue amounts to -13m USD.

What is Epizyme Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-48%

Over the last year, the Cost of Revenue growth was -48%.

Back to Top